220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

Authors:
  • PAP.G. Aftimos
    P.G. Aftimos
  • JCJ. Cortés
    J. Cortés
  • FBF.C. Bidard
    F.C. Bidard
  • VKV. Kaklamani
    V. Kaklamani
  • ABA. Bardia
    A. Bardia
  • PNP. Neven
    P. Neven
  • GSG. Streich
    G. Streich
  • AMA. Montero
    A. Montero
  • FFF. Forget
    F. Forget
  • MRM.A. Mouret Reynier
    M.A. Mouret Reynier
  • JSJ. Sohn
    J. Sohn
  • DTD. Taylor
    D. Taylor

Abstract
No abstract available